{
    "name": "ofatumumab",
    "comment": "Rx",
    "other_names": [
        "Arzerra"
    ],
    "classes": [
        "Antineoplastics",
        "Anti-CD20 Monoclonal Antibodies"
    ],
    "source": "https://reference.medscape.com/drug/arzerra-ofatumumab-999309",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: unknown whether distributed in breast milk; published data suggest neonate/infant does not ingest substantial amount of these maternal antibodies from breast milk, although caution is warranted"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: unknown whether distributed in breast milk; published data suggest neonate/infant does not ingest substantial amount of these maternal antibodies from breast milk, although caution is warranted"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Progressive multifocal leukoencephalopathy (PML) including fatal PML, can occur in patients receiving obinutuzumab"
            ],
            "specific": [
                {
                    "type": "Hepatitis B virus reactivation",
                    "description": [
                        "Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies",
                        "Screen all patients for HBV infection before treatment initiation",
                        "Monitor HBV positive patients during and after treatment",
                        "Discontinue ofatumumab and concomitant medications in the event of HBV reactivation"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Progressive multifocal leukoencephalopathy (PML) resulting in death has occurred with therapy; consider PML in any patient with new-onset of or changes in pre-existing neurological signs or symptoms; if PML is suspected, discontinue therapy and initiate evaluation for PML including neurology consultation",
                "The safety of immunization with live viral vaccines during or following administration of the drug has not been studied; do not administer live viral vaccines to patients who have recently received the drug; the ability to generate an immune response to any vaccine following administration of the drug has not been studied"
            ],
            "specific": [
                {
                    "type": "Tumor lysis syndrome",
                    "description": [
                        "Tumor lysis syndrome (TLS), including the need for hospitalization, reported; patients with high tumor burden and/or high circulating lymphocyte counts (>25 x 10",
                        "9",
                        "/L) are at greater risk for developing TLS",
                        "Consider tumor lysis prophylaxis with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion of the drug; for treatment of TLS, administer aggressive intravenous hydration and anti-hyperuricemic agents, correct electrolyte abnormalities, and monitor renal function"
                    ]
                },
                {
                    "type": "Cytopenias",
                    "description": [
                        "Severe cytopenias, including neutropenia, thrombocytopenia, and anemia, reported; pancytopenia, agranulocytosis, and fatal neutropenic sepsis have occurred in patients who received the drug in combination with chlorambucil",
                        "Grade 3 or 4 late-onset neutropenia (onset at least 42 days after last treatment dose) and/or prolonged neutropenia (not resolved between 24 and 42 days after last treatment dose) reported in patients who received the drug",
                        "Monitor complete blood counts at regular intervals during and after conclusion of therapy, and increase the frequency of monitoring in patients who develop Grade 3 or 4 cytopenias"
                    ]
                },
                {
                    "type": "Infusion reactions",
                    "description": [
                        "The drug can cause serious, including fatal, infusion reactions manifesting as bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac events (eg, myocardial ischemia/infarction, acute coronary syndrome, arrhythmia, bradycardia), back pain, abdominal pain, pyrexia, rash, urticaria, angioedema, cytokine release syndrome, and anaphylactoid/anaphylactic reactions",
                        "Infusion reactions occur more frequently with the first 2 infusions; these reactions may result in temporary interruption or withdrawal of treatment",
                        "Pre-medicate with acetaminophen, an antihistamine, and a corticosteroid",
                        " Infusion reactions may occur despite premedication; interrupt infusion with the drug for infusion reactions of any severity; institute medical management for severe infusion reactions including angina or other signs and symptoms of myocardial ischemia",
                        "If an anaphylactic reaction occurs, immediately and permanently discontinue treatment and initiate appropriate medical treatment"
                    ]
                },
                {
                    "type": "Hepatitis B virus infection",
                    "description": [
                        "Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, has occurred; cases have been reported in patients who are hepatitis B surface antigen (HBsAg) positive and also in patients who are HBsAg negative but are hepatitis B core antibody (anti-HBc) positive",
                        "Reactivation also has occurred in patients who appear to have resolved hepatitis B infection (ie, HBsAg negative, anti-HBc positive, and hepatitis B surface antibody [anti-HBs] positive)",
                        "HBV reactivation is defined as an abrupt increase in HBV replication manifesting as a rapid increase in serum HBV DNA level or detection of HBsAg in a person who was previously HBsAg negative and anti-HBc positive.",
                        "Reactivation of HBV replication is often followed by hepatitis, ie, increase in transaminase levels and, in severe cases, increase in bilirubin levels, liver failure, and death",
                        "Screen all patients for HBV infection by measuring HBsAg and anti-HBc before initiating treatment; for patients who show evidence of hepatitis B infection (HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive), consult physicians with expertise in managing hepatitis B regarding monitoring and consideration for HBV antiviral therapy",
                        "Monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following treatment",
                        "HBV reactivation has been reported for at least 12 months following completion of therapy. In patients who develop reactivation of HBV while receiving the drug, immediately discontinue therapy and any concomitant chemotherapy, and institute appropriate treatment",
                        "Resumption of treatment in patients whose HBV reactivation resolves should be discussed with physicians with expertise in managing hepatitis B; insufficient data exist regarding the safety of resuming therapy in patients who develop HBV reactivation",
                        "Fatal infection due to hepatitis B in patients who have not been previously infected reported; monitor patients for clinical and laboratory signs of hepatitis"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Anemia",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Bronchitis",
            "percent": null
        },
        {
            "name": "Upper respiratory tract infections",
            "percent": null
        },
        {
            "name": "Infusion reaction",
            "percent": null
        },
        {
            "name": "complication",
            "percent": null
        },
        {
            "name": "Cytopenias",
            "percent": null
        },
        {
            "name": "Infection",
            "percent": null
        },
        {
            "name": "pneumonia",
            "percent": null
        },
        {
            "name": "sepsis",
            "percent": null
        },
        {
            "name": "Progressive multifocal leukoencephalopathy",
            "percent": null
        },
        {
            "name": "Hepatitis B reactivation",
            "percent": null
        },
        {
            "name": "Intestinal obstruction",
            "percent": null
        }
    ]
}